Jpmorgan Chase & CO Immucell Corp Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Immucell Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 11 shares of ICCC stock, worth $50. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11
Previous 13
15.38%
Holding current value
$50
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ICCC
# of Institutions
23Shares Held
1.15MCall Options Held
0Put Options Held
0-
Cresset Asset Management, LLC Chicago, IL264KShares$1.21 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA226KShares$1.03 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny149KShares$684,6590.0% of portfolio
-
Bleichroeder LP New York, NY102KShares$465,3000.12% of portfolio
-
Dimensional Fund Advisors LP Austin, TX72.7KShares$332,8830.0% of portfolio
About IMMUCELL CORP
- Ticker ICCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 7,746,860
- Market Cap $35.5M
- Description
- ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive ...